Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  poly ICLC
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 34 for your search:
Start Over
Phase I-II Immunotherapy with Poly ICLC for Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: no age specified
Sponsor:
Protocol IDs: MDA-M-8002
Phase I/II Immunotherapy with Poly-ICLC for Recurrent Melanoma
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: no age specified
Sponsor: NCI
Protocol IDs: EST-PC-680
Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 to 75
Sponsor: Other
Protocol IDs: CDR0000573370, UMDNJ-0120070076, 0120070076, NCT00553683
Vaccination-Dendritic Cells With Peptides for Recurrent Malignant Gliomas
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: Over 18
Sponsor: Other
Protocol IDs: 05-115, RO1 NS055140, NCT00766753
Safety Study of Adjuvant Vaccine to Treat Melanoma Patients
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: GCO 13-1391, NCT01079741
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Temporarily closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 11-094, 902168, NCT01720836
Phase II Immunotherapy with Stabilized Poly-IC (Poly-ICLC) in the Treatment of Refractory Pediatric Solid Tumors
Phase: Phase II
Type: Treatment
Status: Closed
Age: under 18
Sponsor:
Protocol IDs: NCI-79-C-23, NCI-POB-7803
Phase II Study of Human Lymphoblastoid Interferon vs Stabilized Poly-IC (Poly-ICLC) for Acute Myelocytic Leukemia, CLL, and Various Solid Tumors
Phase: Phase II
Type: Treatment
Status: Closed
Age: over 18
Sponsor:
Protocol IDs: NCI-79-C-80, NCI-POB-7901, UMCC-7914
Phase II Immunotherapy with Stabilized Poly-IC (Poly-ICLC) for Previously Treated Children with Acute Leukemia
Phase: Phase II
Type: Treatment
Status: Closed
Age: under 21
Sponsor: NCI
Protocol IDs: CCG-082
Phase II Immunotherapy with Poly ICLC for Refractory Metastatic Breast Cancer
Phase: Phase II
Type: Treatment
Status: Closed
Age: no age specified
Sponsor:
Protocol IDs: MDA-MBDT-8027
Phase II Immunotherapy with Poly-ICLC for Children with Metastatic Neuroblastoma Refractory to Standard Treatment
Phase: Phase II
Type: Treatment
Status: Closed
Age: under 21
Sponsor: NCI
Protocol IDs: CCG-082A
Phase II Immunotherapy with the Interferon Inducer Poly ICLC in Patients with Unresectable Renal Cell Cancer (Summary Last Modified 07/88)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: EST-PA-884, EST-P-A884
Biological Therapy and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000258685, NABTC-0105, NCT00052715
Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: ABTC-0106 CDR0000287012, U01CA062399, ABTC-0106, NABTC01-06, NCT00058123
Radiation Therapy and Temozolomide Followed by Temozolomide and Poly ICLC in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: NABTT-0501 CDR0000454915, U01CA062475, NABTT-0501, NCT00262730
Dendritic Cell Vaccine for Patients With Brain Tumors
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 10-000202, NCT01204684
Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 to 80
Sponsor: Other
Protocol IDs: UPCC 02710, UMGCC 0955, NCT01245673
Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: MCC-16545, NCT01437605
Phase I Evaluation of Poly-ICLC (NSC-301463) in Cancer Patients (Summary last modified 06/97)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: BRMP-8303, NCI-83-C-143, NCI-T83-1257B, T83-1257
Phase IB Trial of Poly ICLC in Combination with IL-2 in Patients with Solid Tumors
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: BRMP-8803A, NCI-88-C-101A, NCI-T88-0005N, T88-0005
Phase I Trial of IFN-A/Poly ICLC in Patients with Advanced Malignancies (Summary Last Modified 06/97)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: BRMP-8915A, NCI-90-C-48A, NCI-T89-0173N, T89-0173
MUC1 Vaccine in Conjunction With Poly-ICLC in Patients With Recurrent and/or Advanced Prostate Cancer
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 05-086, NCT00374049
Safety Study to Test the Safety of HspE7 and Poly-ICLC Given in Patients With Cervical Intraepithelial Neoplasia
Phase: Phase I
Type: Prevention
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: HspE7-00101-0601, NCT00493545
Start Over